Blockade of the expression of sensitization and tolerance by ondansetron, a 5-HT3 receptor antagonist, administered during withdrawal front intermittent and continuous cocaine

被引:29
作者
King, GR [1 ]
Xiong, Z [1 ]
Ellinwood, EH [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA
关键词
5-HT3; receptor; continuous cocaine; intermittent cocaine; ondansetron; sensitization; tolerance; rat;
D O I
10.1007/s002130050508
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The present experiment evaluated the ability of the 5-HT3 antagonist, ondansetron, administered during withdrawal from chronic cocaine administration, to block the expression of sensitization and tolerance induced by the intermittent or continuous administration of cocaine, respectively. Rats were pretreated with 40 mg/kg/per day cocaine for 14 days by either SC injections or osmotic minipumps, or 0.9% saline, administered via osmotic minipump. During the first 5 days of withdrawal from this pretreatment regimen, all rats received a daily SC injection of 0-1.0 mg/kg ondansetron. On day seven of withdrawal from the cocaine pretreatment (2 days after the final ondansetron injection) all subjects received a 15.0 mg/kg IP cocaine challenge. Their behavior was then rated according to the Ellinwood and Balster (1974) scale for 60 min. The results indicated that daily injections of ondansetron, on days 1-5 of withdrawal from the pretreatment regimen, had no significant effect on the subsequent behavioral response to cocaine in the saline control subjects. In contrast, daily injections of ondansetron, on days 1-5 of withdrawal from intermittent cocaine administration, significantly blocked the expression of sensitization. In the continuous cocaine group, ondansetron injections, on days 1-5 of withdrawal from continuous cocaine administration, also blocked the expression of behavioral tolerance. The results therefore indicate that changes in 5-HT3 receptor function are associated with the expression of tolerance and sensitization, respectively.
引用
收藏
页码:263 / 269
页数:7
相关论文
共 52 条
[1]   SUBCHRONIC COCAINE TREATMENT ENHANCES COCAINE-INDUCED DOPAMINE EFFLUX, STUDIED BY INVIVO INTRACEREBRAL DIALYSIS [J].
AKIMOTO, K ;
HAMAMURA, T ;
OTSUKI, S .
BRAIN RESEARCH, 1989, 490 (02) :339-344
[2]   ACTIVATION OF 5-HT3 RECEPTOR BY 1-PHENYLBIGUANIDE INCREASES DOPAMINE RELEASE IN THE RAT NUCLEUS-ACCUMBENS [J].
CHEN, J ;
VANPRAAG, HM ;
GARDNER, EL .
BRAIN RESEARCH, 1991, 543 (02) :354-357
[3]   PRESYNAPTIC DOPAMINE RELEASE IS ENHANCED BY 5-HT3 RECEPTOR ACTIVATION IN MEDIAL PREFRONTAL CORTEX OF FREELY MOVING RATS [J].
CHEN, JP ;
PAREDES, W ;
VANPRAAG, HM ;
LOWINSON, JH ;
GARDNER, EL .
SYNAPSE, 1992, 10 (03) :264-266
[4]   EFFECTS OF THE 5-HT3 RECEPTOR ANTAGONIST, GR38032F, ON RAISED DOPAMINERGIC ACTIVITY IN THE MESOLIMBIC SYSTEM OF THE RAT AND MARMOSET BRAIN [J].
COSTALL, B ;
DOMENEY, AM ;
NAYLOR, RJ ;
TYERS, MB .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 92 (04) :881-894
[5]   NEUROANATOMICAL SITES OF ACTION OF 5-HT3 RECEPTOR AGONIST AND ANTAGONISTS FOR ALTERATION OF AVERSIVE BEHAVIOR IN THE MOUSE [J].
COSTALL, B ;
KELLY, ME ;
NAYLOR, RJ ;
ONAIVI, ES ;
TYERS, MB .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 96 (02) :325-332
[6]   THE PSYCHOPHARMACOLOGY OF 5-HT3 RECEPTORS [J].
COSTALL, B ;
NAYLOR, RJ ;
TYERS, MB .
PHARMACOLOGY & THERAPEUTICS, 1990, 47 (02) :181-202
[7]   SITES OF ACTION OF ONDANSETRON TO INHIBIT WITHDRAWAL FROM DRUGS OF ABUSE [J].
COSTALL, B ;
JONES, BJ ;
KELLY, ME ;
NAYLOR, RJ ;
ONAIVI, ES ;
TYERS, MB .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 36 (01) :97-104
[8]   THE BREADTH OF ACTION OF THE 5-HT3 RECEPTOR ANTAGONISTS [J].
COSTALL, B .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 :3-9
[9]   ONDANSETRON INHIBITS A BEHAVIORAL CONSEQUENCE OF WITHDRAWING FROM DRUGS OF ABUSE [J].
COSTALL, B ;
JONES, BJ ;
KELLY, ME ;
NAYLOR, RJ ;
ONAIVI, ES ;
TYERS, MB .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 36 (02) :339-344
[10]   EXTRAPYRAMIDAL AND MESOLIMBIC INVOLVEMENT WITH STEREOTYPIC ACTIVITY OF D-AMPHETAMINE AND L-AMPHETAMINE [J].
COSTALL, B ;
NAYLOR, RJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1974, 25 (02) :121-129